Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1989 Jul;30(4):205–212. doi: 10.1007/BF01665006

The inhibitory effect of human interferon α on the generation of lymphokine-activated killer activity

Yutaka Tokuda 1, Nobuo Ebina 1, Sidney H Golub 1,✉
PMCID: PMC11038049  PMID: 2598190

Abstract

The generation of lymphokine-activated killer (LAK) activity and the proliferative response to human recombinant interleukin-2 (IL-2) were significantly reduced by the presence of human recombinant leukocyte interferon (IFNα) in cultures of human peripheral blood mononuclear cells (PBMC). Mature natural killer (NK) cells can be depleted from PBMC with the toxic lysosomotropic agentl-leucine methyl ester. The generation of cytotoxic cells from lymphocytes depleted in leucine methyl ester was also inhibited by indicating that the IFN-α effect is not limited to mature cytotoxic NK cells. Depletion of adherent cells from PBMC did not affect the suppression of LAK induction by IFN-α. Surface marker analyses of Tac antigen and transferrin receptor (TfR) showed that the presence of IFNα throughout the culture period significantly suppressed the typical increase in IL-2-induced Tac- and TfR-positive cells. In contrast, IFNα treatment before and after IL-2 culture enhanced LAK cytotoxic activity. Therefore, combinations of these biological response modifiers for clinical use should take into account the dual effect of IFNα on key features of the IL-2 response.

Keywords: Natural Killer, Peripheral Blood Mononuclear Cell, Human Peripheral Blood Mononuclear Cell, Biological Response Modifier, Cytotoxic Natural Killer Cell

Footnotes

This work was supported in part by USPHS grant CA34442. Y. T. is a UCLA visiting scientist from the Department of Surgery, School of Medicine, Tokai University, Kanagawa, Japan and recipient of a fellowship from the University of California Cancer Research Coordinating Committee. N. E. is a UCLA visiting scientist from the Department of Surgery, School of Medicine, Tohoku University, Sendai, Japan

References

  • 1.Besancon F, Bourgeade M, Ugo T. Inhibition of transferrin receptor expression by interferon-α in human lymphoblastoid cells and mitogen-induced lymphocytes. J Biol Chem. 1985;260:13074. [PubMed] [Google Scholar]
  • 2.Blomgren H, Strander H, Cantell K. Effect of human leukocyte interferon on the response of lymphocytes to mitogenic stimuli in vitro. Scand J Immunol. 1974;3:697. doi: 10.1111/j.1365-3083.1974.tb01305.x. [DOI] [PubMed] [Google Scholar]
  • 3.Brunda MJ, Tarnowski D, Davetelis V. Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells. Int J Cancer. 1986;37:787. doi: 10.1002/ijc.2910370522. [DOI] [PubMed] [Google Scholar]
  • 4.Karavodin L, Golub SH. Universal rosetting reagent for the detection of human cell surface markers. J Immunol Methods. 1983;61:293. doi: 10.1016/0022-1759(83)90223-5. [DOI] [PubMed] [Google Scholar]
  • 5.Devos R, Plaetinck G, Cheroutre H, Simons G, Degrave W, Tavernier J, Remaut E, Fiers W. Molecular cloning of human interleukin 2 cDNA and its expression inE. coli . Nucleic Acid Res. 1983;11:4307. doi: 10.1093/nar/11.13.4307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Einat M, Resnitzky D, Kimchi A. Close link between reduction of c-myc expression by interferon and G0/G1 arrest. Nature. 1985;313:597. doi: 10.1038/313597a0. [DOI] [PubMed] [Google Scholar]
  • 7.Goeddel DV, Yelverton E, Ullrich A, Heyneker HL, Miozzari G, Holmes W, Seeburg PH, Dull T, May L, Stebbing N, Crea R, Maeda S, McCandliss R, Sloma A, Tabor JM, Gross M, Familletti PC, Pestka S. Human leukocyte interferon produced bye. coli is biologically active. nature. 1980;287:411. doi: 10.1038/287411a0. [DOI] [PubMed] [Google Scholar]
  • 8.Golub SH, Dorey F, Hara D, Morton DL, Burk MW. Systemic administration of human leukocyte interferon to melanoma patients. I. Effects on natural killer function and cell population. J Natl Cancer Inst. 1982;68:703. [PubMed] [Google Scholar]
  • 9.Golub SH, D'Amore PJ, Rainey M. Systemic administration of human leukocyte interferon to melanoma patients. II. Cellular events associated with changes in natural killer cytotoxicity. J Natl Cancer Inst. 1982;68:711. [PubMed] [Google Scholar]
  • 10.Gray JD, Shau H, Golub SH. Functional studies on the precursors of human lymphokine-activated killer cells. Cell Immunol. 1985;96:338. doi: 10.1016/0008-8749(85)90365-x. [DOI] [PubMed] [Google Scholar]
  • 11.Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Grimm EA, Robb RJ, Roth JA, Neckers LM, Lachman LB, Wilson DJ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med. 1983;158:1356. doi: 10.1084/jem.158.4.1356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Hammer SM, Gillis JM. Effects of recombinant interleukin-2 on resting human T lymphocytes. J Biol Response Mod. 1986;5:36. [PubMed] [Google Scholar]
  • 14.Heron I, Berg K, Cantell K. Regulatory effect of interferon on T cells in vitro. J Immunol. 1976;117:1370. [PubMed] [Google Scholar]
  • 15.Hokland P, Hokland M, Olesen BK, Ernest P. Effect of recombinant alpha interferon on NK and ADCC function in lung cancer patients: results from a phase II trial. J Interferon Res. 1984;4:561. doi: 10.1089/jir.1984.4.561. [DOI] [PubMed] [Google Scholar]
  • 16.Ibayashi Y, Hoon DSB, Golub SH. The regulatory effect of adherent cells on lymphokine activated killer cells. Cell Immunol. 1987;110:365. doi: 10.1016/0008-8749(87)90129-8. [DOI] [PubMed] [Google Scholar]
  • 17.Itoh K, Shiiba K, Shimizu Y, Kumagai K. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-γ(IFN-γ) J Immunol. 1985;134:3124. [PubMed] [Google Scholar]
  • 18.Itoh K, Tilden AB, Kumagai K, Balch CM. Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL2)-induced activated killer (AK) cells. J Immunol. 1985;134:802. [PubMed] [Google Scholar]
  • 19.Krönke M, Leonard WJ, Depper JMG. Sequential expression of genes involved in human T lymphocyte growth and differentiation. J Exp Med. 1985;161:1593. doi: 10.1084/jem.161.6.1593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Lau AS, Hannigan GE, Freedman MH, Williams BRG. Regulation of interferon receptor expression in human blood lymphocytes in vitro and during interferon therapy. J Clin Invest. 1986;77:1632. doi: 10.1172/JCI112480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Leonard WJ, Depper JM, Uchiyama T, Smith KA, Waldmann TA, Greene WC. A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. Nature. 1982;300:267. doi: 10.1038/300267a0. [DOI] [PubMed] [Google Scholar]
  • 22.Lifson J, Raubitschek A, Benike C, Koth K, Ammann A, Sondel P, Engleman E. Purified interleukin-2 induces proliferation of fresh human lymphocytes in the absence of exogenous stimuli. J Biol Response Mod. 1986;5:61. [PubMed] [Google Scholar]
  • 23.Lindemann R, Shau H, Ramsdell F, Bohman R, Golub SH. Generation of cytotoxic lymphocytes from non-cytotoxicl-leucine methyl ester (LME) treated PBL with IL-2. Fed Proc. 1987;46:1226. [Google Scholar]
  • 24.London L, Perussia B, Trinchieri G. Induction of proliferation in vitro of resting human natural killer cells: IL-2 induces into cell cycle most peripheral blood NK cells, but only a minor subset of low density T cells. J Immunol. 1986;137:3845. [PubMed] [Google Scholar]
  • 25.Malkovsky M, Jíra M, Madar J, Malkovska V, Loveland B, Asherson GL. Generation of lymphokine-activated killer cells does not require DNA synthesis. Immunology. 1987;60:471. [PMC free article] [PubMed] [Google Scholar]
  • 26.Maluish AE, Ortaldo JR, Conlon JC, Sherwin SA, Leavitt R, Strong DM, Weirnik P, Oldham RK, Herberman RB. Depression of natural killer cytotoxicity after in vivo administration of recombinant leukocyte interferon. J Immunol. 1983;131:503. [PubMed] [Google Scholar]
  • 27.Neckers LM, Cossman J. Transferrin receptor induction in mitogen-stimulated human T lymphocytes is required for DNA synthesis and cell division and is regulated by interleukin 2. Proc Natl Acad Sci USA. 1983;80:3494. doi: 10.1073/pnas.80.11.3494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Ortaldo JR, Mantovani A, Hobbs D, Rubinstein M, Peska S, Herberman RB. Effects of several species of human leukocyte interferon on cytotoxic activity of NK lymphocytes. Int J Cancer. 1983;31:285. doi: 10.1002/ijc.2910310306. [DOI] [PubMed] [Google Scholar]
  • 29.Ortaldo JR, Mason AT, Gerard JP, Henderson LE, Farrar W, Hopkins RF, III, Herberman RB, Rabin H. Effects of natural and recombinant IL2 on regulation of IFNγ production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects. J Immunol. 1984;133:779. [PubMed] [Google Scholar]
  • 30.Phillips JH, Lanier LL. Dissection of the lymphokineactivated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med. 1986;164:814. doi: 10.1084/jem.164.3.814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol. 1981;1:51. doi: 10.1007/BF00915477. [DOI] [PubMed] [Google Scholar]
  • 32.Ramsdell FJ, Shau H, Golub SH. Role of proliferation in LAK cell development. Cancer Immunol Immunother. 1988;26:139. doi: 10.1007/BF00205607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM. Observations on the systemic administration of autologous lymphokine-activated cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485. doi: 10.1056/NEJM198512053132327. [DOI] [PubMed] [Google Scholar]
  • 34.Rosenberg SA, Spiess PJ, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumorinfiltrating lymphocytes. Science. 1986;223:1318. doi: 10.1126/science.3489291. [DOI] [PubMed] [Google Scholar]
  • 35.Rosenberg SA, Schwarz SL, Spiess PJ. Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alpha interferon, and tumor-infiltrating lymphocytes. J Natl Cancer Inst. 1988;80:1393. doi: 10.1093/jnci/80.17.1393. [DOI] [PubMed] [Google Scholar]
  • 36.Sawada H, Abo T, Sugawara S, Kumagai K. Prerequisite for the induction of lymphokine-activated killer cells from T lymphocytes. J Immunol. 1988;140:3668. [PubMed] [Google Scholar]
  • 37.Shau H, Golub SH. Depletion of NK cells with the lysosomotropic agentl-leucine methyl ester and the in vitro generation of NK activity from NK precursor cells. J Immunol. 1985;134:1136. [PubMed] [Google Scholar]
  • 38.Shau H, Shen D, Golub SH. The role of transferrin in natural killer cell and IL-2-induced cytotoxic cell function. Cell Immunol. 1986;97:121. doi: 10.1016/0008-8749(86)90381-3. [DOI] [PubMed] [Google Scholar]
  • 39.Spina CA, Fahey JL, Durkos-Smith D, Dorey F, Sarna G. Suppression of natural killer cell cytotoxicity in the peripheral blood of patients receiving interferon therapy. J Biol Response Mod. 1983;2:458. [PubMed] [Google Scholar]
  • 40.Sutherland R, Delia D, Schneider C, Newman R, Kemshead J, Greaves M. Ubiquitous cell-surface glycoprotein in tumor cells is proliferation-associated receptor for transferrin. Proc Natl Acad Sci USA. 1981;78:4515. doi: 10.1073/pnas.78.7.4515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Trinchieri G, Matsumoto-Kobayashi M, Clark SC, Seehra J, London L, Perussia B. Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med. 1984;160:1147. doi: 10.1084/jem.160.4.1147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Vose BM, Bonnard GD. Limiting dilution analysis of the frequency of human T cells and large granular lymphocytes proliferating in response to interleukin 2. I. The effect of lectin on the proliferative frequency and cytotoxic activity of cultured lymphoid cells. J Immunol. 1983;130:687. [PubMed] [Google Scholar]
  • 43.Vose BM, Riccardi C, Bonnard GD, Herberman RB. Limiting dilution analysis of the frequency of human T cell and large granular lymphocytes proliferating in response to interleukin 2. II. Regulatory role of interferon on proliferative and cytotoxic precursors. J Immunol. 1983;130:768. [PubMed] [Google Scholar]
  • 44.Zoon KC, Nedden DZ, Hu R, Arnheiter H. Analysis of the steady state binding, internalization, and degradation of human interferon-α2 . J Biol Chem. 1986;261:4993. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES